Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Coherus Oncology, Inc. (CHRS : NSDQ)

• Company Description    Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif. Number of Employees: 306

• Price / Volume Information    Yesterday's Closing Price: $1.29 Daily Weekly Monthly 20 Day Moving Average: 1,267,830 shares Shares Outstanding: 116.23 (millions) Market Capitalization: $149.93 (millions) Beta: 0.88 52 Week High: $2.43 52 Week Low: $0.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.47% 24.25% 12 Week 68.06% 52.65% Year To Date -6.52% -13.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 333 TWIN DOLPHIN DRIVE SUITE 600 - REDWOOD CITY,CA 94065 USA ph: 650-649-3530 fax: - ir@coherus.com http://www.coherus.com

• General Corporate Information    Officers Dennis M. Lanfear - Chief Executive Officer; Chairman and President Bryan McMichael - Chief Financial Officer Georgia Erbez - Director Lee N. Newcomer - Director Charles Newton - Director Peer Information Coherus Oncology, Inc. (CORR.) Coherus Oncology, Inc. (RSPI) Coherus Oncology, Inc. (CGXP) Coherus Oncology, Inc. (BGEN) Coherus Oncology, Inc. (GTBP) Coherus Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 19249H103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 116.23 Most Recent Split Date: (:1) Beta: 0.88 Market Capitalization: $149.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.62 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.25 Price/Cash Flow: 4.43 Price / Sales: 1.05 EPS Growth vs. Year Ago Period: -95.00% vs. Previous Quarter: 4.88% Sales Growth vs. Year Ago Period: -84.22% vs. Previous Quarter: 34.94% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -34.85 03/31/25 - -26.51 12/31/24 - -21.44 Current Ratio 06/30/25 - 1.44 03/31/25 - 1.22 12/31/24 - 1.21 Quick Ratio 06/30/25 - 1.43 03/31/25 - 1.20 12/31/24 - 0.96 Operating Margin 06/30/25 - -107.66 03/31/25 - -67.10 12/31/24 - -48.02 Net Margin 06/30/25 - 125.90 03/31/25 - -66.30 12/31/24 - 10.68 Pre-Tax Margin 06/30/25 - 41.42 03/31/25 - 24.88 12/31/24 - 10.68 Book Value 06/30/25 - 1.03 03/31/25 - -1.58 12/31/24 - -1.14 Inventory Turnover 06/30/25 - 3.83 03/31/25 - 2.59 12/31/24 - 1.94 Debt-to-Equity 06/30/25 - 0.31 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - 23.53 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©